SLC25A6P4

Across TCGA pan-cancer cohorts, SLC25A6P4 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC25A6P4’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where SLC25A6P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC25A6P4 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

CHOL, KIRC, and LUSC are the cancer types where SLC25A6P4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A6P4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	II,III,IV	+0.175	<.001	2	view →
KIRC	Female	IV	−0.101	.041	1	view →
LUSC	All	All	+0.067	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SLC25A6P4–CHOL

Open the CHOL breakdown →